First patient dosed in second Phase 2 add-on Ketamine Trial in Treatment-Resistant Depression (TRD)

HMNC Brain Health (“HMNC” or the “company”), together with Develco pharma, today announced the dosing of the first patient in their second Phase 2 trial with oral prolonged-release Ketamine (KET01) for Treatment-Resistant Depression.